Table 1.
Clinical and baseline demographic data.
Fig 1.
Spearman correlation between anti-JCV antibody index and patients’ age.
The correlation between the rank of patient's age and the rank of anti-JVC antibody index is visualized, i.e. the Spearman correlation coefficient with its significance.
Fig 2.
Evolution of anti-JCV antibody index.
Anti-JCV antibody indices are displayed in seronegative and seropositive patients at the different time points during follow-up. At each visit, the total number of patients, the number of anti-JCV antibody positive patients and their distribution among different index categories are shown. JCV, John Cunningham virus.
Fig 3.
Longitudinal change of anti-JCV serostatus.
Frequency of conversion and reversion of anti-JCV serostatus from baseline throughout follow-up.
Fig 4.
Predictive value of baseline anti-JCV antibody index.
(A) Anti-JCV antibody index in seronegative patients at baseline according to seroconversion status at follow-up. Predictive value of different anti-JCV antibody index levels at baseline for prediction of stable seronegative status at follow-up (AUC: 0.986, p<10−23). (B) Anti-JCV antibody index in seropositive patients at baseline according to seroreversion status at follow-up. Predictive value of different anti-JCV antibody index levels at baseline for prediction of stable seropositive status at follow-up (AUC: 0.976, p<10−15). (C) Anti-JCV antibody index in patients with baseline values ≤0.9 according to the change to a higher index category (>0.9) at follow-up. Predictive value of different anti-JCV antibody index levels at baseline for prediction of stable JCV index ≤0.9 at follow-up (AUC: 0.962, p<10−20). (D) Anti-JCV antibody index in patients with baseline values ≤1.5 according to the change to a higher index category (>1.5) at follow-up. Predictive value of different anti-JCV antibody index levels at baseline for prediction of stable JCV index ≤1.5 at follow-up (AUC: 0.948, p<10−20). Ab, antibody; AUC, area under the curve; BL, baseline; JCV, John Cunningham virus; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; **, *** indicate statistical significance at a P-value <0.01 and <0.001, respectively.
Fig 5.
Percentages of patients switching between different anti-JCV antibody index categories.
(A) Percentage of patients with anti-JCV antibody index ≤0.9 at baseline (n = 66) switching to higher index categories at least once during follow-up. (B) Percentage of patients with positive anti-JCV serostatus and antibody index ≤0.9 at baseline (n = 23) switching to higher index categories at least once during follow-up. (C) Percentage of patients with anti-JCV antibody index >0.9 and ≤1.5 at baseline (n = 19) switching to higher or lower index categories at least once during follow-up. There was no patient remaining within the baseline index category during follow-up. (D) Percentage of patients with anti-JCV antibody index >1.5 at baseline (n = 69) switching to lower index categories at least once during follow-up.
Table 2.
Power to predict stability or change of long-term anti-JCV antibody status.